LBA5 Primary results of the phase III KEYNOTE-412 study: Pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)
Machiels, J-P., Tao, Y., Burtness, B., Tahara, M., Rischin, D., Alves, G.V., Lima, I.P.F., Hughes, B.G.M., Pointreau, Y., Aksoy, S., Laban, S., Greil, R., Burian, M., Hetnal, M., Licitra, L.F., Swaby, R., Zhang, Y., Gumuscu, B., Bidadi, B., Siu, L.L.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
651O Pembrolizumab (pembro) + carboplatin (carbo) + paclitaxel (pacli) as first-line (1L) therapy in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Phase VI KEYNOTE-B10 study
Dzienis, M.R., Cundom, J.E., Fuentes, C.S., Hansen, A.R., Nordlinger, M.J., Pastor, A.V., Oppelt, P., Neki, A., Gregg, R.W., Lima, I.P.F., Franke, F.A., da Cunha Junior, G.F., Tseng, J.E., Loree, T., Joshi, A.J., Mccarthy, J.S., Naicker, N., Sidi, Y., Gumuscu, B., De Castro, G.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article